Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high unmet need for cancer patients. Our pipeline features highly selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors – new approaches to clinically validated targets with transformative potential for patients. We are also leveraging our expertise in targeted protein degradation to discover and develop next generation degrader antibody conjugates (DACs) with novel payloads. We are on a mission to extend the promise of precision medicine to every cancer patient in need.
A Bold, Scientific Approach to the Discovery & Development of Innovative Medicines
The discovery of a new medicine is a complex journey of innovation, determination, and insight where both biology and chemistry orchestrate a potential solution for patients. At Prelude Therapeutics, we go where the science leads us, not constrained within a platform, or by a specific target class or chemical modality, to solve challenging, unmet needs of patients. We strive to turn our scientific insights into safe and effective drugs to improve the lives of people with cancer.
Take a look at what we have achieved and how we were able to do it »
KAT6 is an emerging, clinically validated target in the treatment of ER+ breast cancer and other solid tumors
Selective degradation of KAT6A has potential for improved efficacy and tolerability.
KAT6A
DACs
CDK
inhibitors
JAK2V617F
KAT6 is an emerging, clinically validated target in the treatment of ER+ breast cancer and other solid tumors
Selective degradation of KAT6A has potential for improved efficacy and tolerability.
Novel degrader payloads for next generation DACs
Selective CDK9 and CDK4/6 inhibitors with potential application across a range of cancers now available for partnering.
Mutant selective JAK2V617F JH2 inhibitors that bind in the deep pocket
Our Team
With multiple, diverse first/best-in-class programs already in the clinic, we feel the urgency of applying our team’s expertise to finding the therapies that transform patients’ lives. Our cause is cancer, our purpose is patients, and we strive to develop safe, effective, and durable treatments to help improve patients’ lives.
Press Releases
November 12, 2025
Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 4, 2025
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors